gmp
gmp

Find Clinical Drug Pipeline Developments & Deals by Humanetics

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Genistein

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: BIO 300

            Highest Development Status: Phase II Product Type: Small molecule

            Recipient: Pharmaceutics International

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership August 19, 2020

            Details:

            Partnership will support clinical trial studies of BIO 300 in COVID-19 patients.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Genistein

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: National Institutes of Health

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Funding July 23, 2020

            Details:

            Funding will be used to conduct a placebo-controlled double-blind study to understand if 12 weeks of BIO 300 can mitigate lasting COVID-19 effects in the lungs and improve the quality of life for patients.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Genistein,Paclitaxel,Carboplatin

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase I/ Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 28, 2020

            Details:

            Presentation will provide a summary of data from the recent clinical study with BIO 300 in non-small cell lung cancer patients to mitigate radiotherapy toxicity.